Huijuan Dai

This network meta-analysis pooled 10 phase III randomized controlled trials with over 8,000 patients with unresectable advanced gastric cancer, ranked first-line immune checkpoint inhibitors and targeted agents by SUCRA on time to deterioration across EORTC QLQ-C30, EORTC QLQ-STO22 and EQ-5D domains, and used an exploratory minimum distance criterion to integrate overall survival with health-related quality of life, finding that trastuzumab (HER2-positive population) and tislelizumab (largely biomarker-unselected population) ranked most favorably across most quality-of-life domains, while the composite metric remains exploratory, lacks uncertainty estimates, and should not serve as primary evidence for clinical decision-making.

This network meta-analysis pooled 10 phase III randomized controlled trials with over 8,000 patients with unresectable advanced gastric cancer, ranked first-line immune checkpoint inhibitors and targeted agents by SUCRA on time to deterioration across EORTC QLQ-C30, EORTC QLQ-STO22 and EQ-5D domains, and used an exploratory minimum distance criterion to integrate overall survival with health-related quality of life, finding that trastuzumab (HER2-positive population) and tislelizumab (largely biomarker-unselected population) ranked most favorably across most quality-of-life domains, while the composite metric remains exploratory, lacks uncertainty estimates, and should not serve as primary evidence for clinical decision-making.